Datum Källa Rubrik Typ Alternativ
2024-06-14 Biosergen Bulletin from the annual general meeting on June 14, 2024 in Biosergen AB Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 14 Jun 2024 | Biosergen

Bulletin from the annual general meeting on June 14, 2024 in Biosergen AB

Resolution on adoption of accounts and allocation of the Company’s profits

The annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. The annual general meeting also resolved to allocate the Company’s result in accordance with the proposal from the board meaning that no dividends are paid for the financial year 2023 and that available funds are carried forward.

The Board of Directors and Auditor

It was resolved to discharge the members of the Board of Directors and the Chief Executive Officer from liability in relation to their management of the Company’s operations during the period covered by the audit report.

It was resolved that the number of members of the Board of Directors appointed by the annual general meeting shall be four. It was resolved that the number of auditors should continue to be one.

For the period until the end of the next annual general meeting, Anna Ljung and Robert Molander were newly elected as members of the Board of Directors, and Marianne Kock and Mattias Klintemar were re-elected as members of the Board of Directors. For the same period, Anna Ljung was appointed as chairperson of the Board of Directors, and Marianne Kock was appointed as deputy chairperson of the Board of Directors.

It was further resolved to, for the period until the end of the next Annual General Meeting, re-elect the auditing firm Öhrlings PricewaterhouseCoopers AB (PwC) as auditor. It was noted that the authorized public accountant Johan Engstam would be auditor-in-charge.

Fees to the Board of Directors and the Auditor

It was resolved to approve the fees to the Board of Directors as proposed by the major shareholders, entailing a fee of SEK 400,000 to the chairperson of the Board, SEK 300,000 to the deputy chairperson of the Board, and SEK 200,000 to each of the other Board members who are not employed by the Company.

The annual general meeting further approved the major shareholders’ proposal that the auditor’s fee shall be paid in accordance with customary norms and approved invoice.

Authorization to issue shares etc.

The extraordinary general meeting resolved, in accordance with the Board’s proposal, to authorize the Board of Directors to, during the period until the next annual general meeting, on one or several occasions, with or without preferential rights for the shareholders and with or without conditions on payment in kind, by way of set-off or other conditions, resolve upon the issue of shares, convertibles and/or warrants.

Establishment of a warrant programme for employees and other key persons

It was resolved, in accordance with the Board of Directors’ proposal, to establish a warrant programme for certain employees and other key persons in the Company. It was further resolved, in accordance with the Board of Directors’ proposal, upon a directed issue of not more than 4,236,366 warrants, in order to facilitate the Company’s delivery under the warrant programme.

Establishment of a warrant programme for Board members

It was resolved, in accordance with Östersjöstiftelsen’s proposal, to establish a warrant programme for certain Board members of the Company (excluding any Board members who are also employed by or otherwise engaged by Östersjöstiftelsen). It was further resolved, in accordance with Östersjöstiftelsen’s proposal, upon a directed issue of not more than 1,421,122 warrants, in order to facilitate the Company’s delivery under the warrant programme.

2024-06-12 Biosergen Biosergen AB: Biosergen to welcome two new board members based on election at the Annual General Meeting Pressreleaser Ladda ner | Visa Stäng
2024-06-11 Carlsquare Carlsquare: Final permission received, BSG005 to reach patients Pressreleaser Ladda ner | Visa Stäng
2024-06-11 Biosergen Biosergen AB: Biosergen receives the final permission required to test lead candidate BSG005 in patients with invasive fungal infection. Pressreleaser Ladda ner | Visa Stäng
2024-06-11 Biosergen Biosergen AB: BioStock: Biosergen på väg mot första patientstudien med svampdödande behandling Pressreleaser Visa Stäng
2024-06-11 Biosergen Biosergen AB: BioStock: Biosergen towards first-in-patient trial with antifungal therapy Pressreleaser Visa Stäng
2024-05-31 Biosergen Biosergen AB: Biosergen publishes interim report for first quarter 2024 Rapporter Ladda ner | Visa Stäng
2024-05-17 Biosergen Notice of annual general meeting in Biosergen AB Pressreleaser Ladda ner | Visa Stäng
2024-05-14 Biosergen Biosergen AB: BioStock: Biosergens vd "det är ett globalt hälsohot som kräver handling" Pressreleaser Visa Stäng
2024-05-14 Biosergen Biosergen AB: BioStock: Biosergen's CEO - "this is a global health threat and it needs attention" Pressreleaser Visa Stäng
2024-05-10 Biosergen Biosergen AB: Biosergen publishes 2023 annual report Pressreleaser Ladda ner | Visa Stäng
2024-04-16 Biosergen Biosergen AB: Conversion of paid subscribed units and first day of trading with warrants of series TO3 Pressreleaser Ladda ner | Visa Stäng
2024-04-09 Biosergen Biosergen AB: Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue Pressreleaser Ladda ner | Visa Stäng
2024-03-26 Biosergen Biosergen AB: Biosergen announces the outcome in the rights issue Pressreleaser Ladda ner | Visa Stäng
2024-03-18 Biosergen Biosergen AB: BioStock Investor Pitch: Biosergen Pressreleaser Visa Stäng
2024-03-18 Biosergen Biosergen AB: BioStock Investor Pitch: Biosergen Pressreleaser Visa Stäng
2024-03-15 Biosergen Biosergen AB: Members of the board of directors and management subscribe in ongoing rights issue Pressreleaser Ladda ner | Visa Stäng
2024-03-13 Carlsquare Carlsquare: Research update Biosergen: Rights issue to fund crucial step for lead project Pressreleaser Ladda ner | Visa Stäng
2024-03-12 Biosergen Biosergen AB: BioStock: Emission ska ta Biosergen till första effektdata i människa Pressreleaser Visa Stäng
2024-03-12 Biosergen Biosergen AB: BioStock: Rights issue to give Biosergen first in-human efficacy data Pressreleaser Visa Stäng
2024-03-08 Biosergen Biosergen AB: BioStock: Biosergen angriper osynliga hotet från svampinfektioner Pressreleaser Visa Stäng
2024-03-08 Biosergen Biosergen AB: BioStock: Biosergen attacks invisible threat of fungal infections Pressreleaser Visa Stäng
2024-03-07 Carlsquare Carlsquare: Carlsquare Equity Research interview with Biosergen Pressreleaser Ladda ner | Visa Stäng
2024-03-07 Biosergen Biosergen AB: Biosergens vd till BioStock: "Positiva data ger oss starkt erbjudande" Pressreleaser Visa Stäng
2024-03-07 Biosergen Biosergen AB: Biosergen CEO to BioStock: "Positive data give us a strong value proposition" Pressreleaser Visa Stäng
2024-03-05 Biosergen Biosergen AB: Biosergen publishes prospectus due to rights issue of units Pressreleaser Ladda ner | Visa Stäng
2024-03-01 Biosergen Bulletin from the extraordinary general meeting in Biosergen AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-02-29 Biosergen Biosergen AB: Biosergen publishes interim report for fourth quarter 2023 Pressreleaser Ladda ner | Visa Stäng
2024-02-12 Biosergen Biosergen AB: Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection. Pressreleaser Ladda ner | Visa Stäng
2024-02-02 Carlsquare Carlsquare: Mrkt BUZZ, Biosergen: Rights issue to fund the next clinical step Pressreleaser Ladda ner | Visa Stäng
2024-01-30 Biosergen Notice of Extraordinary general meeting in Biosergen AB Pressreleaser Ladda ner | Visa Stäng
2024-01-30 Biosergen Biosergen AB: Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan Pressreleaser Ladda ner | Visa Stäng
2024-01-16 Carlsquare Carlsquare: Research Update Biosergen: Licensing deal with Alkem and CTA submission Pressreleaser Ladda ner | Visa Stäng
2024-01-12 Biosergen Biosergen AB: Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor Pressreleaser Ladda ner | Visa Stäng
2024-01-12 Biosergen Biosergen AB: Biosergen - Indian collaboration gives boost - Mangold Insight Analys Pressreleaser Ladda ner | Visa Stäng
2023-12-12 Biosergen Biosergen AB: Biosergen's Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy Pressreleaser Ladda ner | Visa Stäng
2023-12-11 Carlsquare Carlsquare: Biosergen, Carlsquare Nordic life science investor day Pressreleaser Ladda ner | Visa Stäng
2023-11-30 Biosergen Biosergen AB: Biosergen publishes interim report for third quarter 2023 Rapporter Ladda ner | Visa Stäng
2023-11-30 Biosergen Biosergen AB changes Certified Adviser to Carnegie Investment Bank AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-10-23 Biosergen Biosergen AB: Abstract presented at the 11th Trends in Medical Mycology publicly available Pressreleaser Ladda ner | Visa Stäng
2023-09-25 Biosergen Biosergen AB: Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections Pressreleaser Ladda ner | Visa Stäng
2023-08-28 Biosergen Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million Pressreleaser Ladda ner | Visa Stäng
2023-08-22 Biosergen The last day of trading in warrants series TO2 in Biosergen AB is today, August 22, 2023 Pressreleaser Ladda ner | Visa Stäng
2023-08-16 Carlsquare Carlsquare: Research Update Biosergen, Q2 2023: Stable in costs but delays in clinical timeline Pressreleaser Ladda ner | Visa Stäng
2023-08-16 Biosergen Biosergen AB: Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management Pressreleaser Ladda ner | Visa Stäng
2023-08-14 Biosergen Biosergen AB: Biosergen publishes interim report for first quarter 2023 Pressreleaser Ladda ner | Visa Stäng
2023-08-11 Biosergen Biosergen AB: The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023 Pressreleaser Ladda ner | Visa Stäng
2023-08-11 Biosergen Biosergen AB: Biosergen publish financial report for second quarter ahead of schedule. Pressreleaser Ladda ner | Visa Stäng
2023-08-07 Biosergen Biosergen AB: Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11) Pressreleaser Ladda ner | Visa Stäng